This study evaluates how quality of life, fatigue, and symptoms change over 2 years in patients receiving treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07030400.
Locations matching your search criteria
United States
Florida
Tampa
Moffitt Cancer CenterStatus: Active
Contact: Sara Tinsley
Phone: 813-745-5792
PRIMARY OBJECTIVES:
I. Compare the different trajectories in HRQOL scores measured by the Functional Assessment of Cancer Therapy –Leukemia version between patients receiving BTKi and BCL2i within 7 days of beginning treatment across eight time points over 2 years following initiation of treatment.
II. Evaluate HRQOL predictors of patients with CLL from age, comorbidity (hematopoietic Comorbidity Index), fatigue (Brief Fatigue Inventory), symptoms (Memorial Symptom Assessment Short Form), frailty (Clinical Frailty Scale) and disease characteristics.
III. Test the moderating effect of treatment with age, comorbidity, and fatigue on HRQOL.
OUTLINE: This is an observational study.
Patients complete surveys and have their medical records reviewed on study.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationMoffitt Cancer Center
Principal InvestigatorSara Tinsley
